Met Life Investment Management, LLC Cogent Biosciences, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 53,368 shares of COGT stock, worth $428,545. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,368
Previous 53,368
-0.0%
Holding current value
$428,545
Previous $449,000
28.29%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding COGT
# of Institutions
172Shares Held
114MCall Options Held
56.7KPut Options Held
40.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$84.1 Million0.31% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.24MShares$74.2 Million8.19% of portfolio
-
Commodore Capital LP New York, NY7.54MShares$60.5 Million6.92% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$58.5 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$55.9 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $528M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...